FINWIRES · TerminalLIVE
FINWIRES

Hong Kong Stocks Slide as Trump-Xi Talks Leave Investors Unimpressed; CARsgen Therapeutics Falls

By

Hong Kong stocks tumbled Friday after U.S. President Donald Trump departed China, with investors left underwhelmed by the outcome of his talks with Chinese President Xi Jinping in Beijing.

The Hang Seng Index fell 1.6%, or 426.31 points, to close at 25,962.73, while the Hang Seng China Enterprises Index dropped 1.9%, or 167.60 points, to finish at 8,691.03.

A brief U.S. summary of Thursday's talks highlighted what the White House described as a mutual commitment to reopening the Strait of Hormuz amid the conflict involving Iran.

There were no signs of progress on potential sales of Nvidia's advanced H200 artificial intelligence chips to China.

Trump also told Fox News that Beijing intends to purchase 200 Boeing aircraft, marking its first order for U.S.-made commercial jets in nearly a decade.

Reuters reported, however, that the deal fell short of market expectations for about 500 planes.

In corporate news, CARsgen Therapeutics (HKG:2171) closed over 10% lower after launching a top-up placement expected to raise about HK$462 million in net proceeds.

VPower Group (HKG:1608) fell 17% after its proposed offshore debt restructuring lapsed after failing to become effective by the longstop date.

Related Articles

Asia

Ichigo Hotel REIT to Sell Tokyo Hotel Asset for 1.58 Billion Yen

Ichigo Hotel REIT Investment (TYO:3463) will sell its Hotel Livemax Nihombashi-Hakozaki property in Tokyo for 1.58 billion yen as part of a portfolio restructuring strategy, according to a Friday filing.The company expects to book a gain on sale of 273 million yen, which it plans to fully distribute as dividends, while using remaining proceeds for future acquisitions and value investments, it said.Ichigo Hotel REIT decided to dispose of the property due to limited growth potential because of its size and structure, it said.

$TYO:3463
Asia

Genrix Biopharma Gets Nod for for Multiple Myeloma Monotherapy Trials

Chongqing Genrix Biopharmaceutical (SHA:688443) received approval from China's National Medical Products Administration for the clinical trials of GR1803 injection, according to a Shanghai bourse filing on Friday.The drug will be tested as a monotherapy in patients with relapsed or refractory multiple myeloma.

$SHA:688443
Asia

Market Chatter: CTCI's Total Projects Under Execution Hit Record NT$500 Billion on AI, Clean Energy Boom

CTCI Engineering's (TWO:9933) new contract value hit nearly NT$75 billion as of early May, lifting the total value of projects under execution close to a record NT$500 billion, CNA reported, citing the company's investor conference.The company attributed the surge to rising demand tied to AI infrastructure and the global shift toward cleaner energy systems. It said high-tech projects made up 41% of new contracts in the first four months of the year, reflecting stronger exposure to data centres, semiconductors and high-performance computing-related infrastructure, according to the report.CTCI also highlighted a recent overseas win involving a US memory chip maker's project in Singapore, the report said.The company is expanding its strategy through a "Technology Engineering Strategic Alliance" with partners including Delta Electronics, Taiwan Polymer Group and Ta Ya Group, while also taking part in overseas industrial park initiatives across markets such as the US, Mexico, Poland and India, the news outlet added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$TWO:9933